

Title (en)

GABA A-RECEPTOR-MODULATORS HAVING NMDA-ANTAGONISTIC ACTIVITY

Title (de)

BETACARBOLINDERIVATE ALS GABA A-REZEPTOR-MODULATOREN MIT NMDA-ANTAGONISTISCHER AKTIVITAET ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN

Title (fr)

MODULATEURS DU RECEPTEUR GABA A A ACTIVITE ANTAGONISTE NMDA

Publication

EP 1411939 A2 20040428 (DE)

Application

EP 02791466 A 20020722

Priority

- DE 10136842 A 20010723
- EP 0208166 W 20020722

Abstract (en)

[origin: WO03011264A2] The invention relates to the use of GABAA receptor modulators having NMDA-antagonistic activity for the production of a medicament for neuroprotection and the combination of GABAA receptor modulators having NMDA-antagonistic effects and alpha -liponic acid or dihydro- alpha -liponic acid.

IPC 1-7

A61K 31/437

IPC 8 full level

A61K 31/437 (2006.01); **C07D 471/04** (2006.01); **A61K 31/385** (2006.01); **A61K 45/00** (2006.01); **A61P 25/00** (2006.01); **A61P 25/28** (2006.01)

CPC (source: EP)

A61K 31/385 (2013.01); **A61K 31/437** (2013.01); **A61P 25/00** (2017.12); **A61P 25/28** (2017.12)

Citation (search report)

See references of WO 03011264A2

Citation (examination)

- WO 0185149 A2 20011115 - UNIV VIRGINIA [US], et al
- BAHRAM ET AL, EUR.J.PHARM., vol. 415, no. 2-3, 2001, pages 135 - 140

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)

WO 03011264 A2 20030213; WO 03011264 A3 20031204; AU 2002333262 A1 20030217; DE 10136842 A1 20030213;
EP 1411939 A2 20040428; JP 2004537567 A 20041216

DOCDB simple family (application)

EP 0208166 W 20020722; AU 2002333262 A 20020722; DE 10136842 A 20010723; EP 02791466 A 20020722; JP 2003516495 A 20020722